Nattokinase for Blood Clotting

Research suggests that nattokinase may support blood clot reduction through multiple mechanisms, including breaking down fibrin and lowering key clotting factors such as fibrinogen, factor VII, and factor VIII. Studies indicate a generally supportive direction across different research approaches, including one small open-label randomized controlled trial in humans, a materials science study examining nattokinase-coated medical membranes, and a laboratory-based drug delivery study using targeted microcapsules. The human trial found meaningful reductions in clotting-related proteins following oral supplementation, while the laboratory and engineering studies demonstrated that nattokinase retains biological activity in applied settings and can effectively dissolve fibrin clots in controlled conditions. However, the evidence base remains limited — the only human clinical trial lacked a placebo control group and enrolled a small number of participants, and much of the supporting research comes from laboratory or materials science contexts rather than clinical populations, meaning stronger conclusions will require larger and more rigorously controlled human studies.